Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

Patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) are treated with salvage regimens and may be considered for high-dose chemotherapy and autologous stem cell transplantation if disease is chemosensitive. Bendamustine is active in indolent B cell lymphomas and chronic lymphoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Vacirca, Jeffrey L., Acs, Peter. I., Tabbara, Imad A., Rosen, Peter. J., Lee, Peter, Lynam, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918114/
https://www.ncbi.nlm.nih.gov/pubmed/23955074
http://dx.doi.org/10.1007/s00277-013-1879-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918114/
https://www.ncbi.nlm.nih.gov/pubmed/23955074
http://dx.doi.org/10.1007/s00277-013-1879-x

Ejemplares similares